Is it possible to use the fracture risk assessment tool (FRAX™) when densitometry is not available?
Gustavo Oyama Watanabe, Isabella Moreira Dias, Luciano Roberto Ribeiro de Marins, Marcela Cristina Marquezani Ferreira, Nathalia Leão Vieira, Victor Ferreira Ramos Colasso, Ana Karina Bartman
Abstract
Objective: To calculate the percentage of women treated at the Climaterium Outpatient Clinic of Hospital Electro Bonini who had a high risk of fracture calculated by FRAX to offer empirical treatment for osteoporosis. Methods: A FRAX ™ questionnaire was applied during consultations at the Climacteric Ambulatory in September 2018. Women under 40 and over 90 years of age and cancer from anywhere were excluded. Results: Of the 74 questionnaires answered, 24 (32.43%) had an increased risk of fracture, and patients were considered to start treatment for osteoporosis. Conclusion: Despite its limitations, the FRAX™ tool is an easy method to apply and estimates the risk of bone fracture on an outpatient basis, helping with early therapeutic management, especially when there is a lack of access to bone densitometry.
Keywords
References
1. Pegoraro T, Padilha E, Conti C, Silva L. Quantificação do risco de fraturas através da ferramenta frax em pacientes com doença renal crônica em hemodiálise. Arq Catarin Med. 2017;46(3):39-58.
2. Pinheiro MM, Camargos BM, Borba VZC, Lazaretti-Castro M. FRAX TM: construindo uma ideia para o Brasil. Arq Bras Endocrinol Metabol. 2009;53(6):783-90. http://dx.doi.org/10.1590/S0004-27302009000600015. PMid:19893924.
3. Veiga Silva AC, da Rosa MI, Fernandes B, Lumertz S, Diniz RM, dos Reis Damiani MEF. Fatores associados à osteopenia e osteoporose em mulheres submetidas à densitometria óssea. Rev Bras Reumatol. 2015;55(3):223-8. http://dx.doi.org/10.1016/j.rbr.2014.08.012. PMid:25440700.
4. Rossi AC, Freire AR, Dornelles RCM. Osteoporose: considerações sobre terapêuticas atuais e metabolismo ósseo. Int J Dent. 2010;9(4):210-4.
5. Amadei SU, Silveira VAS, Pereira AC, Carvalho YR, Rocha RF. A influência da deficiência estrogênica no processo de remodelação e reparação óssea. J Bras Patol Med Lab. 2006;42(1):5-12. http://dx.doi.org/10.1590/S1676-24442006000100003.
6. Pardini D. Terapêutica de reposição hormonal na osteoporose da pós menopausa. Arq Bras Endocrinol Metabol. 1999;43(6):428-32. http://dx.doi.org/10.1590/S0004-27301999000600007.
7. Ramalho AC, Lazaretti-Castro M. Fisiopatologia da osteoporose involutiva. Arq Bras Endocrinol Metabol. 1999;43(6):409-14. http://dx.doi.org/10.1590/S0004-27301999000600004.
8. Radominski SC, Bernardo W, Paula AP, Albergaria B, Moreira C, Fernandes CE, et al. Diretrizes brasileiras para o diagnóstico e tratamento da osteoporose em mulheres na pós-menopausa. Rev Bras Reumatol. 2017;57(Suppl 2):s452-66. http://dx.doi.org/10.1016/j.rbr.2017.06.001.
9. Gali JC. Osteoporose. Acta Ortop Bras. 2001;9(2):53-62. http://dx.doi.org/10.1590/S1413-78522001000200007.
10. Radominski SC, Pinto-Neto AM, Marinho RM, Costa-Paiva LHS, Pereira F, Urbanetz AA, et al. Osteoporose em mulheres na pósmenopausa. Rev Bras Reumatol. 2004;44(6):426-34. http://dx.doi.org/10.1590/S0482-50042004000600006.
11. Meirelles ES. Diagnóstico por imagem na osteoporose. Arq Bras Endocrinol Metabol. 1999;43(6):423-7. http://dx.doi.org/10.1590/S0004-27301999000600006.
12. Silva LK. Avaliação tecnológica em saúde: densitometria óssea e terapêuticas alternativas na osteoporose pós-menopausa. Cad Saude Publica. 2003;19(4):987-1003. http://dx.doi.org/10.1590/S0102-311X2003000400022. PMid:12973565.
13. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al. implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449-58. http://dx.doi.org/10.1007/s00198-008-0559-5. PMid:18292975.
14. Kurth AA, Pfeilschifter J. Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006 Orthopade. 2007;36(7):683-90.
15. Kanis JA, Harvey NC, Johansson H, Oden A, Leslie WD, McCloskey EV. FRAX and fracture prediction without bone mineral density. Climacteric. 2015;18(Suppl 2):2-9. http://dx.doi.org/10.3109/13697137.2015.1092342. PMid:26489076.
16. Wang J, Wang X, Fang Z, Lu N, Han L. The Effect of FRAX on the Prediction of Osteoporotic Fractures in Urban Middle-aged and Elderly Healthy Chinese Adults. Clinics (São Paulo). 2017;72(5):289-93. http://dx.doi.org/10.6061/clinics/2017(05)06. PMid:28591341.
17. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series. Geneva: WHO, 1994.
18. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Clinician’s Guide to Prevention and Treatment of Osteoporosis Osteoporos Int. 2014;25(10):2359-81. http://dx.doi.org/10.1007/s00198-014-2794-2. PMid:25182228.
19. Rocha VM, Gaspar HA, Oliveira CF. Fracture risk assessment in home care patients using the FRAX® tool. Einstein (Sao Paulo). 2018;16(3):eAO4236. PMid:30208152.
20. Felisberto MM, Costi MES, Heluany CCV. Relação entre resultados da FRAX-Brasil e de densitometrias ósseas. Rev Soc Bras Clin Med. 2018;16(1):7-12.
21. Zerbini CAF, Szejnfeld VL, Abergaria BH, McCloskey EV, Johansson H, Kanis JA. Incidence of hip fracture in Brazil and the development of a FRAX model. Arch Osteoporos. 2015;10:224. http://dx.doi.org/10.1007/s11657-015-0224-5. PMid:26303038.
22. Bastos-Silva Y, Aguiar LB, Pinto-Neto AM, Baccaro LF, Costa-Paiva L. Correlation between osteoporotic fracture risk in Brazilian postmenopausal women calculated using the FRAX with and without the inclusion of bone densitometry data. Arch Osteoporos. 2016;11(1):16. http://dx.doi.org/10.1007/s11657-015-0255-y. PMid:27067597.
23. Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M, et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32(2):187-96. http://dx.doi.org/10.1007/s40520-019-01432-y. PMid:32043227.
24. Parsons CM, Harvey N, Shepstone L, Kanis JA, Lenaghan E, Clarke S, et al. Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial. Osteoporos Int. 2020;31(1):67-75. http://dx.doi.org/10.1007/s00198-019-05142-z. PMid:31606826.
25. Sousa CJ, Oliveira MLC. FRAX Tool in Brazil: an integrative literature review following validation. Rev Bras Geriatr Gerontol. 2018;21(1):108-15. http://dx.doi.org/10.1590/1981-22562018021.170129.
Submitted date:
07/29/2020
Accepted date:
03/11/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email